- NewsCategory：
- All Company news Industry news
common105One result
-
0927
NeuCyte Licenses Promisi↕✔ng Novel Compound for Treatment of R↕¥βefractory Epilepsy a&φ↔nd Related Neurological Disorders
NeuCyte, Inc., an innovative biotech co<§¥mpany focused on developing novel treatments ★φλfor neurological disorders, today announced$©∑® that it has entered into •&αan exclusive license agreement with Trillium Ther✘₹apeutics to advance an undisclosed €α∞preclinical compound with α✘× potential utility in tre↔λating refractory epi∑β<→lepsy in the form of Dravet syndrπ≈'↓ome and related disorders.T≠δ♥he compound covered by this agreemen∞≤t has demonstrated higε€hly encouraging activity during studies condu δ§✔cted by the National Institut♠©β¶e of Neurological Disorders an'←≥ d Stroke (NINDS) Epilepsy Therapy γ∑ Screening Program (ETSP) δ. It demonstrates a superior safety a≈↓nd anti-seizure efficacy prof↕δ∏≥ile over NINDS benchm €€ark anti-epileptic drugs (AEDs) in eleven>©→ animal models. It has also demonstrated broad♣♦ efficacy in NIH animal studies for pharmaco-r ∏↓esistant epilepsy.&nbs☆®δp; As a result, this novel agent has gai×₹ ned the prestigious NINDS Red Book stat≠"≠Ωus and been selected as a p₽φromising lead drug candidate."This compound ©→is an exceedingly promising antiseizure drug w≤δhich, although in preclinical develop®÷♠×ment, is quite efficacious in a wi®∑↑de variety of highly predict↓✔♣♥ive seizure models," said Roger J. P≤>≈>orter, MD, Adjunct Profesσ♥÷sor of Neurology at the Unive ₩rsity of Pennsylvania, former Deputy Director oπ≥∞±f NINDS, former Chairman of the Whit♦±¶e House Committee on Brain and Behavior∞✘× al Sciences, and former President of Ame♥₩&βrican Epilepsy Society♠<™. "It may prove very effective for®✔ patients with epilepsy." As a£ first-in-class compound with unique mechanis₩≥m of action profiles≤→, this drug candidate is likel₹★☆y to have activity across a variety↑€ of indications. The favora☆♥ble efficacy and safety profile has also →₽₽™been validated by NeuCyte's proprietary in vitro $human iPSC-derived models."Epilepsy →←is the fourth most common neurological disease£♣ affecting more than 65©δ million people of all ages worldwid ♣e. The complex and multifactorial nature of≥© the disorders makes treatment co§×mplicated and challenging. Up to 40% of new←¶ly diagnosed epilepsy patients are r>'esistant to current therapies which highlight☆€£s the urgent need to develop first-in-class treat✘±ments," said Jacqueline A. French, MD, Chief M→" edical and Innovation Ofφδficer of the Epilepsy Founγ€dation and epileptologist in New ≠ ¥York City. "It is very encouraging to see new deλα βvelopments and therapeutic candi<÷®∞dates in this disease area."Under the terms<₽ of the agreement, TrilliβΩ₩♦um has granted NeuCyte exclusiΩ≈ve, worldwide rights to develop and commercialize÷✘✔δ the compound. "NeuCyte is committed to b≠©±ringing breakthrough therapies$™ββ to epilepsy patients and ♦α☆believe that our advantageouε₹♣s translational technology platform and CNS exper$±¥tise enable us to optimall☆∑∑y advance such therapeutic✔₩∞€ candidates," said Tao Huang, PhD, JD, Presiden₹♥'t and Chief Executive Officer of NeuCyte. "Thδ'₽is licensing agreement allows us to>• expand our pipeline and adv₹♥ance our goal of meeting unmet clinical needs anεσ'™d truly improving patient care an∑¶≈d quality of life."information&n←¶∏bsp;source:pharma focus AsiaThe₹₩ original link:https:https:https://www.pharmaf♣∑ocusasia.com/news/neucyte-liceα§✔₹nses-promising-novel-compoun±✘d-for-treatment-of-refractory-epi∑©€lepsy-and-related-neurologi↕≠cal-disorders2019 Asia-paciΩ★®×fic pharma IP Leader Summit:http://en.zenseeβ♥group.com/p/510934/wil♠ ÷¶l be held in Beijing &≤ nbsp;on November 14-15, and will attract ♥↔¶more than 500 industry experts fromφ domestic and foreign ph σ÷$armaceutical companies, biotechnology coλ<mpanies, governments, associatio•₹×ns, law firms, intellectual property agents β£→and other companies to at •©←tend.Official registration and consultation ch δ←±annels:Contact：AnnPhone: 021-656503∏®05Email：Marketing@zenseegroup.comhttp://en.zen÷✘seegroup.com/p/510934/ -
0926
Ivy Brain Tumor Center and B←αridgeBio Subsidiary QED Therapeutics Announce ColΩ∏λlaboration to Advance Cancer Research a↔€↓nd Treatment OptionsΩ±&Ω
The Ivy Brain Tumor C♦"★enter at Barrow Neurological Institute, tod☆∑ay announced a new collaborφ'¶ation with QED Therapeutics, Inc., a subsidiary≠★ of BridgeBio Pharma, Inc., (Nasdaq:BBIO) to i¥¶nvestigate the FGFR1-3 tyrosine kinase inhibΩ∏÷itor, infigratinib, for the treatment of gliob→×lastoma (GBM). With the goal of addre←✔ssing unmet medical neλ eds for those affected by malignant brain cance∞•r, this collaboration will focus on targetin¶β☆g FGFR (fibroblast growth f≥φ≤✔actor receptor) genetic alterations th $at have been shown to spur growth i>↑<n malignant tumors.“Fi∑>&♠ve to seven percent of ♣₽¶glioblastoma patients’ tumors are dri♦®ven by FGFR signaling,” said Dr. Nader San>↔☆♠ai, director of the Ivy Brain Tumor CenteΩ¥÷r. “We believe our collaboration with Q✔β☆ED Therapeutics will enaδ∏↔★ble us to test how FGFR-driveφ✔©βn GBM tumors respond to infigr§€₽atinib. If proven effec ♥tive, we then intend to®φ move forward new combined drug strategies ∏↓incorporating this ta≥±¥rget.”In the preclinical studies, ≤ the Ivy Center will βσemploy orthotopically →<implanted, well-characterized FGFR3 fusion pati §ent-derived xenograft modelε≠s. This is intended to allow the team to further→↑ explore the extent to which the drug crosεγ•λses the blood-brain barrier♦ and what activity it has in the brain.“We be★"lieve the work we are§&' undertaking with the Ivy Center wΩ☆₹≤ill provide critical insight to shape our clε♠₩inical development strategy for∏δ¶ this disease,“ said Susan Moran, M.D., M.S.C.E.,π' chief medical officer of QED Therapeutics<£>€. “Our hope is that infi♥π>≥gratinib will become the>φ¥↔ backbone of new combination therapies to treat pλ€←σatients with glioblastom§✘λa.”Infigratinib is an orally adminiβ±stered, FGFR1-3 select★<÷÷ive tyrosine kinase inhibit♥←or. QED Therapeutics has obser±σved activity that appea↑♥$rs to be meaningful in clinical trials for cance₽€rs that are driven by erro≥ rs in the FGFR genes. These ×$$include chemotherapy-refractory cholangio™☆€ carcinoma with FGFR2 fusions and adγ¥♦vanced urothelial carcinoma with F'€GFR3 genetic alterations.“The intricacies o✔≤₽f the brain have posed signif↔∏icant challenges for brain cancer researc♠♣™h and the development of therapies,<✔” said Gary Li, head of translational med♦≤$εicine at QED Therapeutics. “We believe coll≥"aborating with the Ivy Brain T•÷✔≤umor Center will enable us to move swλ★♠iftly and further translational resea∞ rch that we hope will unlock the do↔ors to effective treatment options.”inᱧ¥formation source:pharma foσ∑δ↑cus AsiaThe original← ♥ link:https:https://www.pharmafocusasia₩×∞.com/news/ivy-brain-tumor-center-and-bridgebio-s™♠§ubsidiary-qed-therapeutics-announce-colla$λ≠boration-to-advance-cancer-research☆ →-and-treatment-options2019 A®≈sia-pacific pharma IP Leader Summit:http:&<☆//en.zenseegroup.com/p/510934/will be held in&nbs Ωp;Beijing on November 14-15, "✔ and will attract more than 5 ↓00 industry experts from domesε®tic and foreign pharmaceutical£↑↕→ companies, biotechnology compβπ♠≠anies, governments, associations, law firms, ¶™intellectual property ag☆↕ents and other companies to attend.OffiΩ£₽cial registration and consultation channels:Conta✘φ₩ ct：AnnPhone: 021-65650305Em•∑ ail：Marketing@zenseegroup.comhttp://www ×♥.zenseegroup.com/forms/view/22113/ -
0925
I-Mab Biopharma Announces Clinical Collab¶"≥oration to Evaluate TJC4 φ∏±in Combination with KEYTRUDA® (pembrolizumab)
I-Mab Biopharma ("I-Mab"), a China and U.S.- βbased clinical stage biopharmaceutical com"€∑pany exclusively focusing on the discove↔×✔✘ry and development of potential fi↕ αrst-in-class and best-in-class biologics in immu₽↕≈no-oncology and autoimmune diseases, tod$ φ₩ay announced that it has ↔÷ ×entered into a clinical research collaborati♥★•on agreement with MSD, a tradename of Me&πrck & Co., Inc., Kenilworth, NJ., USA↓α, to evaluate the combination of I-Mab's TJC4€γ and MSD's anti-PD-1 therapy, KEYTRUDA® (pembroli←≤zumab) in patients with mu↑γltiple cancer types.Und∞☆λer this collaboration agreement,<δ MSD will supply KEYTRUDA® (δ☆¶↔pembrolizumab) to I-Mab for use in clini↔↔≠♦cal studies in combination♦α→ with TJC4, a fully human anti-CD47 monoclonal ₽€•antibody. Both partie♠÷✔☆s will collaborate on a Phase 1 clinical t↕©♥"rial, based on an agreed and finalized protocol,± to evaluate the safety, pharmacokinetics, ph®♥"armacodynamics and preliminary efficacy'α☆© of TJC4 and KEYTRUDA® i©§n patients with multiple cancer types."TJC4←α♥ is a highly differentiate>★↕πd anti-CD47 antibody currently under clinical ε>development. This collaboration wi•©'$ll provide an excellent opport₽ unity to further explore therapeutic potential♣φ→♠ of combining TJC4 with KEYTRUDA® acr ™¥≈oss different tumor types." s↑βaid Dr. Jingwu Zang, ₹φFounder and Chairman of I-Mab.KEYTRUDA® is a ☆✘←•registered trademark of Merck Sharp & Doh"÷me Corp., a subsidiary of Merck &ε¥ Co., Inc., Kenilworth, NJ, USA.i δ nformation source:pharma focus AsiaThe orig↓↕inal link:https://www.pharmafocusasia.com/news/i-♥×£ mab-biopharma-announces-clin∑¥"φical-collaboration-to×'-evaluate-tjc4-in-combination-with-keγ∞Ω ytruda2019 Asia-pacific pharma IP Le ΩΩλader Summit:http://en.zenseegroup.com/☆εp/510934/ will be he≈✘∞ld in Beijing on Novδember 14-15, and will attract more than 5→π00 industry experts from domestic and foreign pha↕→>$rmaceutical companies,λ™® biotechnology companies, governmen≤®♠ts, associations, law firms, int∞✔ellectual property agents and other co < ≈mpanies to attend.Official r÷®egistration and consultation channels>✘♠:Contact：AnnPhone: 021-65650305Email：Marketing@z✔×enseegroup.comhttp://www.σ₹λzenseegroup.com/forms/view/22φε113/ -
0923
Boehringer Ingelheim Partners with Inflammasome T♠¥herapeutics to Develop Novel Therapies for Pati∏Ωσents with Retinal Diseases
Boehringer Ingelheim and Inflammasome Ther&≤apeutics Inc. (Inflammasome) today annou≈∑•nced they have entered into a co-development anΩ£≈d license agreement to develop up to three ₩β&therapies for patients with retinal dise÷↔®ases. By combining Inflammasome’s uniq®≥<ue intravitreal (IVT) drug delive&→£ry technologies with Boehringer Ingelh£→eim’s compounds from its retinal disease ×✔pipeline portfolio, Boehringer Inα±gelheim aims to develop novel therap©ΩΩies for retinal diseases↓.In 2019 there were an estimated 82 million pa•¥♥≥tients in the seven key countries (U.S., J≥ ♦apan, Germany, U.K., Spain, Italy, France) aff ™ected by one of the thr€$ee major forms of re↔≈π↕tinal disease: Age related macular degeneration (¥∑¶≠AMD), diabetic retinoΩ÷₹pathy (DR), and diabetic macular £↓βedema (DME). Globally, the prev✘α∞alence rates of these anδ∑σ&d other retinal diseases are ₩₹↔ expected to increase over the next 10 years prim₩☆₹δarily due to aging populations and the global di±γδabetes epidemic. Despite therapeutic ad♣↓₽vances in some disease areas during the pa©™αst years, the real world results areπ∏↓ poor, and there are ♦ no or only limited treatment options in many area↕₹s, resulting in an overall high unmet need. ÷≥The collaboration betwe<σ₩ en Boehringer IngelheiΩ¥♦m and Inflammasome aims to addresλ∞s this challenge by using In♦®flammasome’s technology to deliver therapeu★÷tics in a biodegradable gel formuε∏ lation into the eye.“We are delighted♣♣ ≠ to enter into a collaboratio✔¶n with a company of Boehr♣πα©inger Ingelheim’s stature,” said Pau 맩l Ashton, Chief Executive Officer o¥δf Inflammasome Thera∑₹✘±peutics. “We look forward to worki≈<ng with their team to leverage our$♣ respective technologies and exp®π₩ertise to develop new therapies for devastat £ing retinal diseases leading to blindness. This∏π©≈ collaboration fits our strat←××egy of advancing the company via ≈εboth collaborations and in≥ "ternal development.”“✔σβBoehringer Ingelheim is looking forward ≤♣☆to developing Inflammasome’s novel technol ≠§φogy for the delivery of our first-in- clε•ass retinal disease compounds wπΩ≈✘orking jointly with Inflammasome’s highly exper>•δienced scientific team,” said Clive R. Wood, PhD,Ω Senior Corporate Vice President, Discove£π★™ry Research at Boehringer Ingelheim. “Tβλ£his will enable us t♠≥o develop a broad range of>↕¶↕ novel therapy optioσλns for the many patients with retinalλ↑♥ diseases waiting urgently for better an↑★™αd new therapy options.”Boehringer Ingelheim take s a holistic approach i≥✘α®n the development of novel retinal dise♦♠ase therapies, targeting key mechanism∞↕↔≥s in the pathogenesi↓✔✘s of retinal diseases. The company has bui≠₹lt a comprehensive pipelinσλλe portfolio of next generation th₽★←erapy approaches in various stages of developme£§∑♦nt up to Phase 2 in macular degeneration, ☆£diabetic retinal diseases and bey₽♥ond. Inflammasome’s novel delivery technology u£₩₩sing a long-acting degradable IVT impl≈≈ant complements this portfol𠧕io.Inflammasome is entitled to receive up tλ"o $160 million in up-front,≠ research and development support and milδ€estone gated development pφ₹εayments as well as tiered royalties based on ✔Ω∑&future commercial sales of develope ₩£"d products and other milestonλ←'¶es due on commercialization♦•Ω.information source:pharma ↑"focus AsiaThe original link:https://wwwφ>.pharmafocusasia.com/news/boehringer-in"♣₹gelheim-partners-with-inflamm®asome-therapeutics-to-α® ₽develop-novel-therapies-for-patients-γ™→with-retinal-diseases2019 Asia-pacific ph↕♣×∑arma IP Leader Summit: http://en.zenseegroup.co✔↕₽£m/p/510934/will be held in Beijing&nλbsp; on November 14-15δ♠, and will attract more★ ¶ than 500 industry experts fr ≠om domestic and foreign pharmaceutical cβγ>ompanies, biotechnology co₽mpanies, governments, associations, law firm¶₩₩s, intellectual property agents and o₩©§ther companies to attend.Official registrat₩££ion and consultation channels:Cont✘≠act：AnnPhone: 021-65650305Email：Marketing@z≤βenseegroup.comhttp://www.zenseegr§αoup.com/forms/view/22113/ -
0920
Clene Nanomedicine, Inc. Announces Selection of C♦≈♦NM-Au8 for the Harvard Led HEALEY ALS P♦≤→σlatform Trial, a Clinical Trial for Amyotrophic"ᙶ Lateral Sclerosis
Clene Nanomedicine, Inc., a cli✔₹λnical-stage biopharmaceutical company, ∑α announced today that the Sαⶶean M. Healey & AMG Cen✘₹αter for ALS at Mass General has sele£✔♥cted CNM-Au8 for inclusion↓δ" in the first ever Platform Trial for the treatme §"nt of amyotrophic lateral sclerosis (A£πδ©LS).The Healey Center issueδ™ d a call earlier this year for the best the×∑♣rapeutic candidates to apply for entry i≥&nto the HEALEY ALS Platform Trial. They receive≠↔☆d responses from nearly 30 applicants across ten≤ countries. Members from the Heal©∞≥ey Center Science Advisor↑→y Committee, a group of reno®®Ωwned ALS scientists,γ$≈β chose the top five therapeutic™≤← candidates, including Clene's lead clinical€'¶$ asset, CNM-Au8. The selection of CNM- ↓→↕Au8 into the Healey ALS Platfor£•€"m Trial includes substantial financial su★ππ÷pport and provides access to over 50 expert AL↑↓S clinical trial sites across the Un✘×ited States."Our goal," said Merit Cuβ÷δ∑dkowicz, MD, MSc, Director of the☆®✘ Healey Center, "is to lower th£₩e barriers for our phar'≤₩ma and academic colleagues to bring&☆Ω• their exciting therapies for ALS forward to clin♥×®εical trials. We are deter₽ mined to accelerate therapy development for ALε←γS."Important preclini☆←'λcal work supporting the effort with CNM-Au8 ≤♦was performed in the >>laboratory of Nicholas J. Maragakis, Dire✘₹÷ctor of the ALS Center for Ce↔ε₽ ll Therapy and Regeneration Research at Johns Hop ™$kins, using human induced pluripotent stem cell÷★©s from ALS patients. Dr. Mara₩•±×gakis is Chair of Clene's Scienti₩™fic Advisory Board fo≈¥r ALS.Dr. Jonathan Glass, Professor§×® of Neurology and Patho Ωlogy at Emory University School of Medicine>✔γ, as well as Director of the Emor∏£→y ALS Center, remarked, "CN♥M-Au8 is quite an interesting compound that i α&s ready for testing inλα✘← ALS clinical trials. Its inclusion in th £ε♠e Platform Trial initia←₩¶tive is an excellent way to move forw♣δard for the development of CNM-Au8✔®₽₽ as a potential therapeutic for ALS.""We are →☆×very pleased Clene's CNM-Ω'¥₩Au8 has been selected for pa↕¶ ∏rticipation in the Healey ALS Platform T £rial. We believe the unique mechanism of CNM-Au8 €→£represents a promisin÷♦σg new approach for the treatment of neurode≤☆generative diseases, including ALS, witΩ≈♣§h the potential for meaningful impact for >δthe community of people diagn∏osed with this devastating& and debilitating dis®$'ease," said Rob Etherin₩©≥gton, President and CEO of Clene. "We $δare continuing the development of C㕧NM-Au8 in several cliε±∏nical studies set to launch λδ λlater this year."2019 Asia-pacific pha♥÷"≥rma IP Leader Summit: http://en.z₽φαenseegroup.com/p/510934/will b≈™e held in Beijing ≤'; on November 14-15, and will att<Ω¶ract more than 500 industry expe↕αrts from domestic an€↕d foreign pharmaceutical ☆φcompanies, biotechnologα♥& y companies, governments, associations, la¥w firms, intellectual property agents ×"↓and other companies to attend.Official r€∑☆egistration and consultation channels:Contac♣Ωt：AnnPhone: 021-65650305Email：Marketing@zen ≤&seegroup.comhttp://www.z∑™₹enseegroup.com/forms/view/22113/
Contact Us
Zensee_Daystar online
© 2011-2016